gabapentin has been researched along with Peripheral Nerve Diseases in 116 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to evaluate the efficacy of gabapentin treatment in dry eye disease (DED) and neuropathic ocular pain." | 9.41 | Is gabapentin effective in dry eye disease and neuropathic ocular pain? ( Ongun, GT; Ongun, N, 2021) |
| " Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN." | 9.17 | Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. ( Atalay, H; Biyik, Z; Gaipov, A; Guney, F; Solak, Y; Turk, S, 2013) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 9.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)." | 9.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| " A significant decrease in pain scores with gabapentin was seen in the neuropathic pain group (paired t-test, p < ." | 9.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "This paper reviews the pharmacology and clinical effectiveness of gabapentin in the treatment of neuropathic pain." | 8.82 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| " The search terms included pregabalin, PD144723, CI-1008, gabapentin, and neuropathic pain." | 8.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 7.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "To determine the utility of substitution of pregabalin (PGB) for gabapentin (GBP) therapy in the relief of neuropathic pain (NeP) in patients with peripheral neuropathy (PN)." | 7.76 | Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. ( Toth, C, 2010) |
| "This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain." | 7.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain." | 7.74 | A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007) |
| "We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain." | 7.72 | Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 7.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 7.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day." | 6.69 | Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998) |
| "Neuropathic pain is a common and potentially treatable cause of considerable lifelong morbidity." | 6.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Gabapentin has been shown to be efficacious in numerous smaller clinical studies, case reports, and chart reviews in a variety of neuropathic pain syndromes." | 6.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| "This study aims to evaluate the efficacy of gabapentin treatment in dry eye disease (DED) and neuropathic ocular pain." | 5.41 | Is gabapentin effective in dry eye disease and neuropathic ocular pain? ( Ongun, GT; Ongun, N, 2021) |
| " The most common adverse reactions (incidence ≥ 20%) with single-agent use are fatigue, nausea, and anorexia." | 5.39 | Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment. ( Katsenos, S; Panagou, C; Psara, A, 2013) |
| " Women with breast cancer were randomized into two groups of paclitaxel chemotherapy with gabapentin 300 mg/three times a day orally or placebo for 2 weeks started at day 1 of each paclitaxel cycle." | 5.30 | Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial. ( Aghili, M; Akrami, S; Esmati, E; Ghalehtaki, R; Kalaghchi, B; Mousavi, N; Sotoudeh, S; Zare, M, 2019) |
| "Paclitaxel can cause an acute pain syndrome (P-APS), considered to be an acute form of neuropathy and chronic chemotherapy-induced peripheral neuropathy (CIPN)." | 5.22 | Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial. ( Atherton, PJ; Lafky, J; Loprinzi, CL; Pachman, DR; Ruddy, KJ; Seisler, D; Shinde, SS; Soori, G, 2016) |
| " Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN." | 5.17 | Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. ( Atalay, H; Biyik, Z; Gaipov, A; Guney, F; Solak, Y; Turk, S, 2013) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 5.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| " Gabapentin (GBP) is effective in painful diabetic neuropathy and postherpetic neuralgia and its effectiveness on painful HIV-SN has been reported anecdotally." | 5.11 | A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. ( Arendt, G; Braun, JS; Hahn, K; Husstedt, IW; Maschke, M; Schielke, E; Straube, ME; von Giesen, HJ, 2004) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| " A significant decrease in pain scores with gabapentin was seen in the neuropathic pain group (paired t-test, p < ." | 5.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)." | 5.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| " Multiple multicentre randomised controlled trials have shown clear efficacy of gabapentin and pregabalin for postherpetic neuralgia and painful diabetic neuropathy." | 4.84 | Antiepileptic drugs in the treatment of neuropathic pain. ( Eisenberg, E; Krivoy, N; River, Y; Shifrin, A, 2007) |
| "This paper reviews the pharmacology and clinical effectiveness of gabapentin in the treatment of neuropathic pain." | 4.82 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| " The search terms included pregabalin, PD144723, CI-1008, gabapentin, and neuropathic pain." | 4.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " Acute morphine or gabapentin treatment partly attenuated allodynia in males, but not females." | 4.12 | Persistent sensory changes and sex differences in transgenic mice conditionally expressing HIV-1 Tat regulatory protein. ( Bagdas, D; Bigbee, J; Caillaud, M; Damaj, MI; Hauser, KF; Knapp, PE; McKiver, B; Nass, SR; Ondo, O; Paris, JJ; Toma, W; Warncke, UO, 2022) |
| "We identified 52,249 patients with neuropathy on gabapentinoids, 5,246 patients with neuropathy on SNRIs, 19,820 patients with dementia on cholinesterase inhibitors, and 3,130 patients with PD on dopamine agonists." | 3.96 | Association of out-of-pocket costs on adherence to common neurologic medications. ( Banerjee, M; Burke, JF; Callaghan, BC; Esper, GJ; Kerber, KA; Magliocco, B; Reynolds, EL; Skolarus, LE, 2020) |
| "Muscle cramps associated with PNH respond well to symptomatic treatment, particularly with carbamazepine and gabapentin." | 3.83 | Therapeutic Implications of Peripheral Nerve Hyperexcitability in Muscle Cramping: A Retrospective Review. ( Hobson-Webb, LD; Hurst, RL, 2016) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 3.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "To determine the utility of substitution of pregabalin (PGB) for gabapentin (GBP) therapy in the relief of neuropathic pain (NeP) in patients with peripheral neuropathy (PN)." | 3.76 | Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. ( Toth, C, 2010) |
| "This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain." | 3.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "Gabapentin is used in analgesic treatment of neuropathic pain, and large interindividual variation has been observed in the pharmacokinetics (PK) of the drug." | 3.75 | A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. ( Carlsson, KC; Eriksen, HO; Hoem, NO; Karlsson, MO; Moberg, ER; van de Schootbrugge, M, 2009) |
| "We compared the inhibitory action of gabapentin, which is used to treat neuropathic pain, on mechanical allodynia induced by chemotherapeutic agents, paclitaxel, oxaliplatin, and vincristine, in mice." | 3.75 | Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. ( Andoh, T; Fujita, M; Gauchan, P; Ikeda, K; Kato, A; Kuraishi, Y; Sasaki, A, 2009) |
| "The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain." | 3.74 | A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007) |
| "We have previously demonstrated that gabapentin supraspinally activates the descending noradrenergic system to ameliorate pain hypersensitivity in mice with partial nerve ligation." | 3.74 | Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice. ( Ono, H; Takasu, K; Tanabe, M, 2008) |
| " In the current study, we evaluated the behavioral effects of two standard drugs used clinically for neuropathic pain, the anticonvulsant gabapentin and antidepressant imipramine, in rats at different times after peripheral nerve injury." | 3.73 | The effect of antinociceptive drugs tested at different times after nerve injury in rats. ( Borsook, D; Hama, AT, 2005) |
| "We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain." | 3.72 | Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 3.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 3.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "3%) patients reported adverse events." | 2.87 | Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea. ( Jin, JY; Kang, JH; Kim, BS; Ko, YH; Kwon, JH; Park, HJ; Park, SY; Woo, IS, 2018) |
| "Duloxetine, pregabalin and duloxetine plus gabapentin were generally safe and tolerable for the treatment of DPNP." | 2.79 | Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. ( Irving, G; Malcolm, S; Raskin, J; Risser, RC; Tanenberg, RJ, 2014) |
| "Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day." | 2.69 | Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998) |
| "The review outlines the latest description of the most-relevant rodent models of CIPN enabling comparison between chemotherapeutics, dosing regimen, rodent strain, and sex." | 2.53 | Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics. ( Duggett, NA; Flatters, SJL; Hopkins, HL, 2016) |
| "Neuropathic pain is a common and potentially treatable cause of considerable lifelong morbidity." | 2.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Gabapentin has been shown to be efficacious in numerous smaller clinical studies, case reports, and chart reviews in a variety of neuropathic pain syndromes." | 2.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| "The treatment with gabapentin or LLLT significantly decreased the raised level in total cholesterol in DNP but could not decrease the elevated level of triglycerides, while LDL cholesterol decreased significantly in DNP treated with gabapentin but not affected by LLLT." | 1.48 | Efficiencies of Low-Level Laser Therapy (LLLT) and Gabapentin in the Management of Peripheral Neuropathy: Diabetic Neuropathy. ( Abdel-Wahhab, KG; Daoud, EM; El Gendy, A; Mannaa, FA; Mourad, HH; Saber, MM, 2018) |
| " The most common adverse reactions (incidence ≥ 20%) with single-agent use are fatigue, nausea, and anorexia." | 1.39 | Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment. ( Katsenos, S; Panagou, C; Psara, A, 2013) |
| "We describe a 23-year-old woman with neuritis ossificans involving the tibial, common peroneal and lateral sural nerves." | 1.37 | Neuritis ossificans of the tibial, common peroneal and lateral sural cutaneous nerves. ( Eisen, R; Katz, LD; Lindskog, D, 2011) |
| "Many drugs approved for neuropathic pain engage spinal noradrenergic and cholinergic systems for analgesia." | 1.37 | A tropomyosine receptor kinase inhibitor blocks spinal neuroplasticity essential for the anti-hypersensitivity effects of gabapentin and clonidine in rats with peripheral nerve injury. ( Eisenach, JC; Hayashida, K, 2011) |
| " Single, parenteral dosing of donepezil (1, 1." | 1.36 | Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies. ( Andersen, LM; Bjerrum, OJ; Folkesson, A; Honoré, PH; Kristensen, P, 2010) |
| "Gabapentin has been used effectively for neuropathic pain with mild side effects." | 1.35 | Gabapentin and sexual dysfunction: report of two cases. ( Dalal, A; Zhou, L, 2008) |
| "Neuropathic pain is a clinical manifestation characterized by the presence of spontaneous pain, allodynia and hyperalgesia." | 1.33 | Development and expression of neuropathic pain in CB1 knockout mice. ( Castañé, A; Célérier, E; Ledent, C; Maldonado, R; Martín, M; Parmentier, M; Valverde, O, 2006) |
| "Gabapentin (GBP) has been shown to be effective in animal models of neuropathic pain as well as in chronic pain patients." | 1.33 | Effects of gabapentin on spontaneous discharges and subthreshold membrane potential oscillation of type A neurons in injured DRG. ( Duan, JH; Hu, SJ; Xing, JL; Yang, RH, 2005) |
| "Six children with cerebral palsy are presented who developed neuropathic pain following multilevel orthopedic surgery." | 1.33 | Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and review. ( Lauder, GR; White, MC, 2005) |
| "Paclitaxel (Taxol) is a widely used chemotherapeutic agent in the treatment of several tumors." | 1.33 | Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. ( Hald, A; Inoue, M; Matsumoto, M; Ueda, H; Xie, W, 2006) |
| " Hill slope coefficients for the tested anticonvulsants indicate that the dose-response curve was less steep for gabapentin than for phenytoin, carbamazepine and ethosuximide." | 1.32 | Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats. ( Jevtovic-Todorovic, V; Rastogi, AJ; Todorovic, SM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (6.90) | 18.2507 |
| 2000's | 66 (56.90) | 29.6817 |
| 2010's | 34 (29.31) | 24.3611 |
| 2020's | 8 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Yogeeswari, P | 1 |
| Ragavendran, JV | 1 |
| Sriram, D | 1 |
| Nageswari, Y | 1 |
| Kavya, R | 1 |
| Sreevatsan, N | 1 |
| Vanitha, K | 1 |
| Stables, J | 1 |
| Field, MJ | 2 |
| Li, Z | 1 |
| Schwarz, JB | 1 |
| Payne, JE | 1 |
| Bonnefous, C | 1 |
| Symons, KT | 1 |
| Nguyen, PM | 1 |
| Sablad, M | 1 |
| Rozenkrants, N | 1 |
| Zhang, Y | 1 |
| Wang, L | 1 |
| Yazdani, N | 1 |
| Shiau, AK | 1 |
| Noble, SA | 1 |
| Rix, P | 1 |
| Rao, TS | 1 |
| Hassig, CA | 1 |
| Smith, ND | 1 |
| Mastrangelo, S | 1 |
| Rivetti, S | 1 |
| Triarico, S | 1 |
| Romano, A | 1 |
| Attinà, G | 1 |
| Maurizi, P | 1 |
| Ruggiero, A | 1 |
| Toma, W | 1 |
| Paris, JJ | 1 |
| Warncke, UO | 1 |
| Nass, SR | 1 |
| Caillaud, M | 1 |
| McKiver, B | 1 |
| Ondo, O | 1 |
| Bagdas, D | 1 |
| Bigbee, J | 1 |
| Knapp, PE | 1 |
| Hauser, KF | 1 |
| Damaj, MI | 1 |
| Pandey, P | 1 |
| Kumar, A | 1 |
| Pushpam, D | 1 |
| Khurana, S | 1 |
| Malik, PS | 1 |
| Gogia, A | 1 |
| Arunmozhimaran, E | 1 |
| Singh, MB | 1 |
| Chandran, DS | 1 |
| Batra, A | 1 |
| Uysal Tan, F | 1 |
| Koc, RS | 1 |
| Erkek Ozturk Durmaz, E | 1 |
| Tuncez Akyurek, F | 1 |
| Krajewski, P | 1 |
| Szepietowski, JC | 1 |
| Reynolds, EL | 1 |
| Burke, JF | 1 |
| Banerjee, M | 1 |
| Kerber, KA | 1 |
| Skolarus, LE | 1 |
| Magliocco, B | 1 |
| Esper, GJ | 1 |
| Callaghan, BC | 1 |
| Selvy, M | 1 |
| Pereira, B | 1 |
| Kerckhove, N | 1 |
| Busserolles, J | 1 |
| Farsi, F | 1 |
| Guastella, V | 1 |
| Merle, P | 1 |
| Pezet, D | 1 |
| Balayssac, D | 1 |
| Kim, BS | 1 |
| Jin, JY | 1 |
| Kwon, JH | 1 |
| Woo, IS | 1 |
| Ko, YH | 1 |
| Park, SY | 1 |
| Park, HJ | 1 |
| Kang, JH | 1 |
| Abdel-Wahhab, KG | 1 |
| Daoud, EM | 1 |
| El Gendy, A | 1 |
| Mourad, HH | 1 |
| Mannaa, FA | 1 |
| Saber, MM | 1 |
| Magnowska, M | 1 |
| Iżycka, N | 1 |
| Kapoła-Czyż, J | 1 |
| Romała, A | 1 |
| Lorek, J | 1 |
| Spaczyński, M | 1 |
| Nowak-Markwitz, E | 1 |
| Aghili, M | 1 |
| Zare, M | 1 |
| Mousavi, N | 1 |
| Ghalehtaki, R | 1 |
| Sotoudeh, S | 1 |
| Kalaghchi, B | 1 |
| Akrami, S | 2 |
| Esmati, E | 1 |
| Ongun, N | 1 |
| Ongun, GT | 1 |
| Atalay, H | 2 |
| Solak, Y | 2 |
| Biyik, Z | 2 |
| Gaipov, A | 2 |
| Guney, F | 2 |
| Turk, S | 2 |
| Hershman, DL | 1 |
| Lacchetti, C | 1 |
| Dworkin, RH | 1 |
| Lavoie Smith, EM | 1 |
| Bleeker, J | 1 |
| Cavaletti, G | 1 |
| Chauhan, C | 1 |
| Gavin, P | 1 |
| Lavino, A | 1 |
| Lustberg, MB | 1 |
| Paice, J | 1 |
| Schneider, B | 1 |
| Smith, ML | 1 |
| Smith, T | 1 |
| Terstriep, S | 1 |
| Wagner-Johnston, N | 1 |
| Bak, K | 1 |
| Loprinzi, CL | 3 |
| Irving, G | 1 |
| Tanenberg, RJ | 1 |
| Raskin, J | 1 |
| Risser, RC | 1 |
| Malcolm, S | 1 |
| Shinde, SS | 1 |
| Seisler, D | 1 |
| Soori, G | 1 |
| Atherton, PJ | 1 |
| Pachman, DR | 1 |
| Lafky, J | 1 |
| Ruddy, KJ | 1 |
| Bonnet, U | 1 |
| Ossowski, A | 1 |
| Schubert, M | 1 |
| Gall, H | 1 |
| Steinkamp, I | 1 |
| Richter, LE | 1 |
| Khalil-Boutros, Y | 1 |
| Nefedev, A | 1 |
| Kuhlmann, R | 1 |
| Hopkins, HL | 1 |
| Duggett, NA | 1 |
| Flatters, SJL | 1 |
| Hurst, RL | 1 |
| Hobson-Webb, LD | 1 |
| Ward, RE | 1 |
| Veerula, VL | 1 |
| Ezra, N | 1 |
| Travers, JB | 1 |
| Mousdicas, N | 1 |
| Pongcharoen, P | 1 |
| Fleischer, AB | 1 |
| Şavk, E | 1 |
| Hayashida, K | 2 |
| Eisenach, JC | 2 |
| Ho, TW | 1 |
| Backonja, M | 2 |
| Ma, J | 1 |
| Leibensperger, H | 1 |
| Froman, S | 1 |
| Polydefkis, M | 1 |
| Pigatto, PD | 1 |
| Guzzi, G | 1 |
| Carlsson, KC | 1 |
| van de Schootbrugge, M | 1 |
| Eriksen, HO | 1 |
| Moberg, ER | 1 |
| Karlsson, MO | 1 |
| Hoem, NO | 1 |
| Linam, WM | 1 |
| Wesselkamper, K | 1 |
| Gerber, MA | 1 |
| Prommer, EE | 1 |
| Chiechio, S | 1 |
| Zammataro, M | 1 |
| Caraci, F | 1 |
| Rampello, L | 1 |
| Copani, A | 1 |
| Sabato, AF | 2 |
| Nicoletti, F | 1 |
| Eker, HE | 1 |
| Cok, OY | 1 |
| Aribogan, A | 1 |
| Gauchan, P | 1 |
| Andoh, T | 2 |
| Ikeda, K | 1 |
| Fujita, M | 1 |
| Sasaki, A | 2 |
| Kato, A | 1 |
| Kuraishi, Y | 2 |
| Omori, Y | 1 |
| Kagaya, K | 1 |
| Enomoto, R | 1 |
| Nojima, H | 1 |
| Takahata, H | 1 |
| Mao, YF | 1 |
| Liu, XR | 1 |
| Liao, XZ | 1 |
| Lv, YH | 1 |
| Xu, H | 1 |
| Deng, XM | 1 |
| Yan, SK | 1 |
| Xiong, YC | 1 |
| Zhang, WD | 1 |
| Domínguez Suárez, E | 1 |
| Pardo-Sobrino, F | 1 |
| Pensado Castiñeiras, A | 1 |
| Cores Viqueira, MJ | 1 |
| López-Rouco, M | 1 |
| Gatti, A | 1 |
| Carucci, A | 1 |
| Bertini, L | 1 |
| Mammucari, M | 1 |
| Occhioni, R | 1 |
| Devor, M | 1 |
| Tanabe, M | 2 |
| Takasu, K | 2 |
| Ono, H | 2 |
| Toth, C | 1 |
| Arai, YC | 1 |
| Matsubara, T | 1 |
| Shimo, K | 1 |
| Suetomi, K | 1 |
| Nishihara, M | 1 |
| Ushida, T | 1 |
| Kobayashi, K | 1 |
| Suzuki, C | 1 |
| Kinoshita, A | 1 |
| Kondo, M | 1 |
| Matsubara, S | 1 |
| Hayashi, R | 1 |
| Tohyama, Y | 1 |
| Nishida, K | 1 |
| Arakawa, M | 1 |
| Attal, N | 2 |
| Cruccu, G | 2 |
| Baron, R | 1 |
| Haanpää, M | 1 |
| Hansson, P | 1 |
| Jensen, TS | 1 |
| Nurmikko, T | 2 |
| Kolosov, A | 1 |
| Goodchild, CS | 1 |
| Cooke, I | 1 |
| Bar Ad, V | 1 |
| Sirven, JI | 1 |
| Gemignani, F | 1 |
| Ferrari, G | 1 |
| Vitetta, F | 1 |
| Giovanelli, M | 1 |
| Macaluso, C | 1 |
| Marbini, A | 1 |
| Pérez, C | 1 |
| Navarro, A | 1 |
| Saldaña, MT | 1 |
| Masramón, X | 1 |
| Rejas, J | 3 |
| Finch, CK | 1 |
| Eason, J | 1 |
| Usery, JB | 1 |
| Folkesson, A | 1 |
| Honoré, PH | 1 |
| Andersen, LM | 1 |
| Kristensen, P | 1 |
| Bjerrum, OJ | 1 |
| Katz, LD | 1 |
| Lindskog, D | 1 |
| Eisen, R | 1 |
| Sicras-Mainar, A | 1 |
| Rejas-Gutiérrez, J | 1 |
| Navarro-Artieda, R | 1 |
| Planas-Comes, A | 1 |
| Hosseini-Zare, MS | 1 |
| Dashti-Khavidaki, S | 1 |
| Mahdavi-Mazdeh, M | 1 |
| Ahmadi, F | 1 |
| Tan, IL | 1 |
| Polydefkis, MJ | 1 |
| Ebenezer, GJ | 1 |
| Hauer, P | 1 |
| McArthur, JC | 1 |
| Katsenos, S | 1 |
| Psara, A | 1 |
| Panagou, C | 1 |
| Gerlinger, I | 1 |
| Arcos, M | 1 |
| Palanca, JM | 1 |
| Montes, F | 1 |
| Barrios, C | 1 |
| Surges, R | 1 |
| Feuerstein, TJ | 1 |
| Gonzalez, MI | 1 |
| Tallarida, RJ | 1 |
| Singh, L | 1 |
| Bortalanza, LB | 1 |
| Ferreira, J | 1 |
| Hess, SC | 1 |
| Delle Monache, F | 1 |
| Yunes, RA | 1 |
| Calixto, JB | 2 |
| Glanzman, RL | 1 |
| Sarantopoulos, C | 1 |
| McCallum, B | 1 |
| Sapunar, D | 1 |
| Kwok, WM | 1 |
| Hogan, Q | 1 |
| Todorovic, SM | 1 |
| Rastogi, AJ | 1 |
| Jevtovic-Todorovic, V | 1 |
| Kassuya, CA | 1 |
| Silvestre, AA | 1 |
| Rehder, VL | 1 |
| Reyes-García, G | 2 |
| Medina-Santillán, R | 2 |
| Rocha-González, HI | 1 |
| Granados-Soto, V | 2 |
| Bennett, MI | 1 |
| Simpson, KH | 1 |
| Dost, R | 1 |
| Rostock, A | 1 |
| Rundfeldt, C | 1 |
| Yetimalar, Y | 1 |
| Gürgör, N | 1 |
| Başoğlu, M | 1 |
| Ilag, VL | 1 |
| Decosterd, I | 1 |
| Allchorne, A | 1 |
| Woolf, CJ | 1 |
| Dahl, JB | 1 |
| Mathiesen, O | 1 |
| Møiniche, S | 1 |
| Back, SK | 1 |
| Won, SY | 1 |
| Hong, SK | 1 |
| Na, HS | 1 |
| Hahn, K | 1 |
| Arendt, G | 1 |
| Braun, JS | 1 |
| von Giesen, HJ | 1 |
| Husstedt, IW | 1 |
| Maschke, M | 1 |
| Straube, ME | 1 |
| Schielke, E | 1 |
| Derbyshire, E | 1 |
| Martin, D | 1 |
| Caram-Salas, NL | 1 |
| Braune, S | 1 |
| Lauder, GR | 1 |
| White, MC | 1 |
| Yang, RH | 1 |
| Xing, JL | 1 |
| Duan, JH | 1 |
| Hu, SJ | 1 |
| Hama, AT | 1 |
| Borsook, D | 1 |
| Kroin, JS | 1 |
| Buvanendran, A | 1 |
| Cochran, E | 1 |
| Tuman, KJ | 1 |
| Dani, K | 1 |
| Ramachandran, R | 1 |
| Capell, HA | 1 |
| Madhok, R | 1 |
| Castañé, A | 1 |
| Célérier, E | 1 |
| Martín, M | 1 |
| Ledent, C | 1 |
| Parmentier, M | 1 |
| Maldonado, R | 1 |
| Valverde, O | 1 |
| Gilron, I | 1 |
| Max, MB | 1 |
| Suzuki, R | 1 |
| Dickenson, AH | 1 |
| Ross, JR | 1 |
| Goller, K | 1 |
| Hardy, J | 1 |
| Riley, J | 1 |
| Broadley, K | 1 |
| A'hern, R | 1 |
| Williams, J | 1 |
| Baillie, JK | 1 |
| Power, I | 1 |
| Guay, DR | 1 |
| Gálvez, R | 1 |
| Marsal, C | 1 |
| Vidal, J | 1 |
| Ruiz, M | 2 |
| Matsumoto, M | 1 |
| Inoue, M | 1 |
| Hald, A | 1 |
| Xie, W | 1 |
| Ueda, H | 1 |
| Ribera, MV | 1 |
| Masrramón, X | 1 |
| Coderre, TJ | 1 |
| Kumar, N | 1 |
| Lefebvre, CD | 1 |
| Yu, JS | 1 |
| Mishriki, YY | 1 |
| Norman, P | 1 |
| Eisenberg, E | 1 |
| River, Y | 1 |
| Shifrin, A | 1 |
| Krivoy, N | 1 |
| Rao, RD | 1 |
| Michalak, JC | 1 |
| Sloan, JA | 1 |
| Soori, GS | 1 |
| Nikcevich, DA | 1 |
| Warner, DO | 1 |
| Novotny, P | 1 |
| Kutteh, LA | 1 |
| Wong, GY | 1 |
| Loosemore, MP | 1 |
| Bordeaux, JS | 1 |
| Bernhard, JD | 1 |
| Galluzzi, KE | 1 |
| Dalal, A | 1 |
| Zhou, L | 1 |
| Benbouzid, M | 1 |
| Choucair-Jaafar, N | 1 |
| Yalcin, I | 1 |
| Waltisperger, E | 1 |
| Muller, A | 1 |
| Freund-Mercier, MJ | 1 |
| Barrot, M | 1 |
| Haslam, C | 1 |
| Rosner, H | 1 |
| Rubin, L | 1 |
| Kestenbaum, A | 1 |
| Rosenberg, JM | 1 |
| Harrell, C | 1 |
| Ristic, H | 1 |
| Werner, RA | 1 |
| de Rosayro, AM | 1 |
| Newshan, G | 1 |
| McCaffery, M | 1 |
| Merren, MD | 1 |
| Brasseur, L | 1 |
| Parker, F | 1 |
| Chauvin, M | 1 |
| Bouhassira, D | 1 |
| de Oliveira, JO | 1 |
| Fortini, I | 1 |
| de Andrade, MP | 1 |
| Vadivelu, N | 1 |
| Berger, J | 1 |
| Nicholson, B | 1 |
| LaBuda, CJ | 1 |
| Fuchs, PN | 1 |
| Batoon, SB | 1 |
| Vela, AT | 1 |
| Dave, D | 1 |
| Wahid, Z | 1 |
| Conetta, R | 1 |
| Iakovou, C | 1 |
| Banzuela, M | 1 |
| Corradini, L | 1 |
| Briscini, L | 1 |
| Ongini, E | 1 |
| Bertorelli, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies: Observational and Cross-sectional Study[NCT03854864] | 216 participants (Actual) | Observational | 2019-01-14 | Completed | |||
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients[NCT04732455] | 60 participants (Actual) | Interventional | 2021-01-15 | Completed | |||
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| Effect of Cryotherapy in Controlling Peripheral Neuropathy in Cancer Children[NCT04536207] | 60 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)[NCT04780854] | Phase 2 | 68 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)[NCT04299893] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2020-11-30 | Recruiting | ||
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain[NCT00385671] | Phase 4 | 407 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM)[NCT04246619] | Phase 4 | 254 participants (Actual) | Interventional | 2019-11-12 | Terminated (stopped due to The statistical analysis will still provide relevant results with the same statistical power as initially planned.COVID-19 pandemic prolonged the recruiting period and consequently affected the costs of the clinical trial.) | ||
| Effects of Intra-Operative Ropivaciane Epidural Injection on Post-Operative Outcomes Following Elective Lumbar Fusion[NCT03035656] | Phase 4 | 228 participants (Anticipated) | Interventional | 2019-03-01 | Not yet recruiting | ||
| Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients[NCT03847311] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-05-03 | Recruiting | ||
| Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain[NCT00637975] | Phase 2 | 80 participants (Anticipated) | Interventional | 2007-09-30 | Completed | ||
| Effect of Two Different Doses of Oral Pregabalin Premedication for Postoperative Pain Relief After Gynecological Surgeries[NCT04708353] | 90 participants (Anticipated) | Interventional | 2020-08-20 | Recruiting | |||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy: Controlled Double-blind Study[NCT03419949] | 0 participants | Expanded Access | Available | ||||
| Effects of Transverse Abdominis Plane Block Guided by Ultrasound on the Postoperative Analgesia and Quality of Lives Among the Patients Undergo Inguinal Hernia Repair[NCT02292095] | Phase 4 | 260 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| The Efficacy Of Gabapentin In The Management Of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind, Placebo-Controlled, Crossover Trial[NCT00027963] | Phase 3 | 100 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy[NCT03571334] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-07-08 | Recruiting | ||
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis[NCT05603702] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-03-17 | Recruiting | ||
| Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used[NCT02693821] | Phase 4 | 122 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A 21-item, patient-completed questionnaire to assess characteristics of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score. There is a four-point scale for each item ranging from 0 to 3. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.57 |
| Duloxetine | -3.13 |
| Gabapentin + Duloxetine | -2.54 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | kilogram (Least Squares Mean) |
|---|---|
| Pregabalin | 1.00 |
| Duloxetine | -2.39 |
| Gabapentin + Duloxetine | -1.06 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Pregabalin | -1.30 |
| Duloxetine | 0.80 |
| Gabapentin + Duloxetine | 1.05 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Gabapentin + Duloxetine | -2.39 |
| Duloxetine | -2.62 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.12 |
| Duloxetine | -2.62 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the daily nighttime pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.30 |
| Duloxetine | -2.71 |
| Gabapentin + Duloxetine | -2.49 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the daily worst pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.59 |
| Duloxetine | -3.08 |
| Gabapentin + Duloxetine | -2.86 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 65 |
| Duloxetine | 68 |
| Gabapentin + Duloxetine | 72 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 59 |
| Duloxetine | 64 |
| Gabapentin + Duloxetine | 68 |
Elevated heart rate: >=100 beats per minute (bpm) + an increase of >=10 bpm if baseline <100 bpm. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 2 |
| Duloxetine | 9 |
| Gabapentin + Duloxetine | 6 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 48 |
| Duloxetine | 50 |
| Gabapentin + Duloxetine | 47 |
A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). (NCT00385671)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 3.03 |
| Duloxetine | 3.01 |
| Gabapentin + Duloxetine | 2.83 |
Number of participants who discontinued. The reasons for discontinuation are presented in the participant flow. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 38 |
| Duloxetine | 51 |
| Gabapentin + Duloxetine | 36 |
This is the number of days required to first achieve a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved. It is based on a comparison between baseline and post-baseline scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | days (Median) |
|---|---|
| Pregabalin | 56.0 |
| Duloxetine | 35.0 |
| Gabapentin + Duloxetine | 28.0 |
This is the number of days required to first achieve a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved. It is based on a comparison between baseline and post-baseline scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | days (Median) |
|---|---|
| Pregabalin | 35.0 |
| Duloxetine | 28.0 |
| Gabapentin + Duloxetine | 28.0 |
The Portland Neurotoxicity Scale is a 15-item, patient-completed questionnaire designed to assess the degree of impact of anti-epileptic drug therapy on a number of cognitive and somatomotor parameters. Categories: better=negative change in score; same=no change in score; worse=positive change in score. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| better, total; n=122, n=126, n=128 | same, total; n=122, n=126, n=128 | worse, total; n=122, n=126, n=128 | better, cognitive toxicity; n=126, n=129, n=128 | same, cognitive toxicity; n=126, n=129, n=128 | worse, cognitive toxicity; n=126, n=129, n=128 | better, somatomotor toxicity; n=122, n=126, n=129 | same, somatomotor toxicity; n=122, n=126, n=129 | worse, somatomotor toxicity; n=122, n=126, n=129 | |
| Duloxetine | 84 | 5 | 37 | 80 | 6 | 43 | 74 | 19 | 33 |
| Gabapentin + Duloxetine | 86 | 4 | 38 | 82 | 5 | 41 | 74 | 19 | 36 |
| Pregabalin | 68 | 8 | 46 | 75 | 9 | 42 | 60 | 15 | 47 |
The Resource Utilization Scale measures direct and indirect costs (collected only for US sites). Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Inpatient costs include costs associated with hospitalizations and time spent in emergency rooms and psychiatric rooms. Outpatient costs include costs associated with visits to various health care providers, home health care by health care providers, and partial care. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| hours worked, greater, n=86, n=90, n=83 | hours worked, same, n=86, n=90, n=83 | hours worked, lower, n=86, n=90, n=83 | hours volunteered, greater, n=86, n=91, n=82 | hours volunteered, same, n=86, n=91, n=82 | hours volunteered, lower, n=86, n=91, n=82 | psychiatric visits, greater, n=92, n=93, n=90 | psychiatric visits, same, n=92, n=93, n=90 | psychiatric visits, lower, n=92, n=93, n=90 | outpatient group visits, greater, n=91, n=92, n=91 | outpatient group visits, same, n=91, n=92, n=91 | outpatient group visits, lower, n=91, n=92, n=91 | outpatient ind. visits, greater, n=91, n=88, n=90 | outpatient ind. visits, same, n=91, n=88, n=90 | outpatient ind. visits, lower, n=91, n=88, n=90 | days of partial care, greater, n=93, n=95, n=90 | days of partial care, same, n=93, n=95, n=90 | days of partial care, lower, n=93, n=95, n=90 | nights of partial care, greater, n=92, n=95, n=91 | nights of partial care, same, n=92, n=95, n=91 | nights of partial care, lower, n=92, n=95, n=91 | ER visits-psychiatric, greater, n=93, n=94, n=91 | ER visits-psychiatric, same, n=93, n=94, n=91 | ER visits-psychiatric, lower, n=93, n=94, n=91 | ER visits-nonpsychiatric, greater,n=91, n=95, n=88 | ER visits-nonpsychiatric, same,n=91, n=95, n=88 | ER visits-nonpsychiatric, lower,n=91, n=95, n=88 | phone mental health, greater,n=94, n=95, n=90 | phone mental health, same,n=94, n=95, n=90 | phone mental health, lower,n=94, n=95, n=90 | nonpsychiatric visits, greater, n=89, n=94, n=83 | nonpsychiatric visits, same, n=89, n=94, n=83 | nonpsychiatric visits, lower, n=89, n=94, n=83 | unpaid care, greater, n=84, n=87, n=86 | unpaid care, same, n=84, n=87, n=86 | unpaid care, lower, n=84, n=87, n=86 | missed work caregiver, greater, n=6, n=9, n=5 | missed work caregiver, same, n=6, n=9, n=5 | missed work caregiver, lower, n=6, n=9, n=5 | paid care, greater, n=60, n=58, n=58 | paid care, same, n=60, n=58, n=58 | paid care, less, n=60, n=58, n=58 | |
| Duloxetine | 12 | 66 | 12 | 8 | 77 | 6 | 0 | 91 | 2 | 0 | 92 | 0 | 1 | 84 | 3 | 1 | 94 | 0 | 1 | 94 | 0 | 0 | 94 | 0 | 4 | 85 | 6 | 1 | 93 | 1 | 20 | 46 | 28 | 0 | 87 | 0 | 0 | 8 | 1 | 0 | 58 | 0 |
| Gabapentin + Duloxetine | 13 | 59 | 11 | 10 | 66 | 6 | 2 | 84 | 4 | 1 | 89 | 1 | 4 | 81 | 5 | 2 | 87 | 1 | 2 | 89 | 0 | 0 | 91 | 0 | 4 | 78 | 6 | 2 | 87 | 1 | 18 | 45 | 20 | 0 | 85 | 1 | 0 | 5 | 0 | 0 | 58 | 0 |
| Pregabalin | 10 | 65 | 11 | 7 | 66 | 13 | 2 | 88 | 2 | 0 | 90 | 1 | 3 | 84 | 4 | 2 | 91 | 0 | 1 | 91 | 0 | 0 | 91 | 2 | 3 | 83 | 5 | 1 | 92 | 1 | 24 | 44 | 21 | 2 | 82 | 0 | 0 | 6 | 0 | 0 | 60 | 0 |
14-item subject-rated scale assessing changes in sexual activity and functioning; structured interview/questionnaire, designed to measure medication related changes in sexual functioning. 5 dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; orgasm. Total score: obtained across all 5 dimensions, ranges from 14 to 70. Subscale scores: desire/frequency=2-10; desire/interest=3-15; pleasure=1-5; arousal=3-15; orgasm=3-15. Higher scores = better sexual functioning. Categories: better=positive change in score; same=no change in score; worse=negative change in score. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| male, total, better; n=62, n=67, n=66 | male, total, same; n=62, n=67, n=66 | male, total, worse; n=62, n=67, n=66 | female, total, better; n=39, n=42, n=43 | female, total, same; n=39, n=42, n=43 | female, total, worse; n=39, n=42, n=43 | male, pleasure, better; n=64, n=67, n=69 | male, pleasure, same; n=64, n=67, n=69 | male, pleasure, worse; n=64, n=67, n=69 | female, pleasure, better; n=40, n=42, n=43 | female, pleasure, same; n=40, n=42, n=43 | female, pleasure, worse; n=40, n=42, n=43 | male, desire/frequency, better; n=65, n=67, n=69 | male, desire/frequency, same; n=65, n=67, n=69 | male, desire/frequency, worse; n=65, n=67, n=69 | female, desire/frequency, better; n=42, n=42, n=43 | female, desire/frequency, same; n=42, n=42, n=43 | female, desire/frequency, worse; n=42, n=42, n=43 | male, desire/interest, better; n=65, n=67, n=70 | male, desire/interest, same; n=65, n=67, n=70 | male, desire/interest, worse; n=65, n=67, n=70 | female, desire/interest, better; n=42, n=42, n=45 | female, desire/interest, same; n=42, n=42, n=45 | female, desire/interest, worse; n=42, n=42, n=45 | male, arousal, better; n=65, n=67, n=70 | male, arousal, same; n=65, n=67, n=70 | male, arousal, worse; n=65, n=67, n=70 | female, arousal, better; n=40, n=42, n=45 | female, arousal, same; n=40, n=42, n=45 | female, arousal, worse; n=40, n=42, n=45 | male, orgasm, better; n=64, n=67, n=69 | male, orgasm, same; n=64, n=67, n=69 | male, orgasm, worse; n=64, n=67, n=69 | female, orgasm, better; n=40, n=42, n=43 | female, orgasm, same; n=40, n=42, n=43 | female, orgasm, worse; n=40, n=42, n=43 | |
| Duloxetine | 26 | 9 | 32 | 23 | 5 | 14 | 11 | 40 | 16 | 16 | 21 | 5 | 20 | 29 | 18 | 12 | 21 | 9 | 18 | 19 | 30 | 18 | 14 | 10 | 24 | 29 | 14 | 18 | 10 | 14 | 18 | 31 | 18 | 17 | 13 | 12 |
| Gabapentin + Duloxetine | 31 | 11 | 24 | 18 | 7 | 18 | 21 | 32 | 16 | 6 | 32 | 5 | 24 | 23 | 22 | 12 | 24 | 7 | 26 | 17 | 27 | 16 | 17 | 12 | 23 | 33 | 14 | 15 | 16 | 14 | 17 | 29 | 23 | 11 | 16 | 16 |
| Pregabalin | 24 | 9 | 29 | 13 | 5 | 21 | 13 | 39 | 12 | 10 | 23 | 7 | 12 | 36 | 17 | 11 | 21 | 10 | 20 | 19 | 26 | 13 | 12 | 17 | 20 | 28 | 17 | 11 | 14 | 15 | 12 | 29 | 23 | 15 | 13 | 12 |
Presented are numbers of participants who discontinued due to a change from baseline in laboratory analytes or vital signs. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Increased blood creatinine | Increased blood glucose | |
| Duloxetine | 0 | 0 |
| Gabapentin + Duloxetine | 1 | 0 |
| Pregabalin | 0 | 1 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | millimeter mercury (Least Squares Mean) | |
|---|---|---|
| Diastolic | Systolic | |
| Duloxetine | 2.24 | -3.08 |
| Gabapentin + Duloxetine | -0.79 | -2.08 |
| Pregabalin | 0.18 | -3.31 |
A self-reported scale that measures the interference of pain in the past 24 hours on enjoyment of life. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.63 | -2.09 |
| Gabapentin + Duloxetine | 5.02 | -2.33 |
| Pregabalin | 4.38 | -1.82 |
A self-reported scale that measures the interference of pain in the past 24 hours on mood. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.08 | -1.85 |
| Gabapentin + Duloxetine | 4.10 | -1.43 |
| Pregabalin | 3.42 | -1.46 |
A self-reported scale that measures the interference of pain in the past 24 hours on normal work. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.98 | -1.86 |
| Gabapentin + Duloxetine | 5.15 | -1.88 |
| Pregabalin | 4.61 | -1.63 |
A self-reported scale that measures the interference of pain in the past 24 hours on relations with other people. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 3.08 | -1.27 |
| Gabapentin + Duloxetine | 3.29 | -1.17 |
| Pregabalin | 2.96 | -0.97 |
A self-reported scale that measures the interference of pain in the past 24 hours on sleep. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.97 | -2.12 |
| Gabapentin + Duloxetine | 5.40 | -2.50 |
| Pregabalin | 4.91 | -2.29 |
A self-reported scale that measures the interference of pain in the past 24 hours on walking ability. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.52 | -2.56 |
| Gabapentin + Duloxetine | 5.79 | -2.09 |
| Pregabalin | 5.25 | -1.88 |
A self-reported scale that measures the interference of pain in the past 24 hours on general activity. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.03 | -2.38 |
| Gabapentin + Duloxetine | 5.03 | -1.86 |
| Pregabalin | 4.24 | -1.51 |
The Interference scores range from 0 (does not interfere) to 10 (completely interferes). There are 7 questions assessing the interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.61 | -2.00 |
| Gabapentin + Duloxetine | 4.83 | -1.90 |
| Pregabalin | 4.25 | -1.62 |
A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.65 | -2.44 |
| Gabapentin + Duloxetine | 5.75 | -2.29 |
| Pregabalin | 5.53 | -1.80 |
A self-reported scale that measures the severity of pain based on the least pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.18 | -1.55 |
| Gabapentin + Duloxetine | 4.07 | -1.54 |
| Pregabalin | 4.23 | -1.27 |
A self-reported scale that measures the severity of pain based on the pain right now. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.03 | -2.24 |
| Gabapentin + Duloxetine | 5.36 | -2.19 |
| Pregabalin | 4.98 | -1.77 |
A self-reported scale that measures the severity of pain based on the worst pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 Weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 6.87 | -3.02 |
| Gabapentin + Duloxetine | 7.00 | -2.64 |
| Pregabalin | 6.73 | -2.34 |
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.47 | -1.16 |
| Gabapentin + Duloxetine | 4.40 | -1.13 |
| Pregabalin | 4.27 | -1.06 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | millimole/liter (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 8.45 | 0.19 |
| Gabapentin + Duloxetine | 7.99 | 0.67 |
| Pregabalin | 8.24 | 0.16 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | percent (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 7.51 | -0.01 |
| Gabapentin + Duloxetine | 7.16 | 0.07 |
| Pregabalin | 7.57 | -0.12 |
Aspartate aminotransferase = AST Alanine aminotransferase = ALT Gamma glutamyl transferase = GGT Alkaline phosphatase = AlkPhos (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units/liter (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| baseline, AST, n=119, n=121, n=118 | change, AST, n=119, n=121, n=118 | baseline, ALT, n=120, n=122, n=120 | change, ALT, n=120, n=122, n=120 | baseline, GGT, n=121, n=123, n=120 | change, GGT, n=121, n=123, n=120 | baseline, AlkPhos, n=121, n=123, n=120 | change, AlkPhos, n=121, n=123, n=120 | |
| Duloxetine | 22.84 | -0.52 | 25.04 | -0.16 | 34.29 | -3.03 | 83.74 | 0.55 |
| Gabapentin + Duloxetine | 23.42 | -0.48 | 24.39 | 0.03 | 43.93 | -2.55 | 82.18 | 1.78 |
| Pregabalin | 22.55 | 1.12 | 23.88 | -0.13 | 40.80 | 1.17 | 84.97 | 2.80 |
The LSEQ assesses the effects of psychoactive compounds on sleep and early morning behavior. Participants mark a series of 100 mm line analogue scales, indicating the direction and magnitude of any changes in behavioral state they experience following administration of the drug. Scores are represented in millimeters, higher scores indicate better sleep and better early morning behavior. Subscale score ranges: GTS=0-300, QOS=0-200, AFS=0-200, BFW=0-300. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| GTS, n=122, n=119, n=118 | QOS, n=121, n=118, n=118 | AFS, n=122, n=118, n=118 | BFW, n=124, n=115, n=118 | |
| Duloxetine | 17.40 | 7.39 | 8.14 | 21.04 |
| Gabapentin + Duloxetine | 14.75 | 9.64 | 11.86 | 14.33 |
| Pregabalin | 10.96 | 9.32 | 10.02 | 19.67 |
The Portland Neurotoxicity Scale is a 15-item, patient-completed questionnaire designed to assess the degree of impact of anti-epileptic drug therapy on a number of cognitive and somatomotor parameters. The total score ranges from 15-135 with higher scores indicating more toxicity. The cognitive toxicity score ranges from 10-90 and the somatomotor toxicity score ranges from 5-45, for both higher scores indicate more toxicity. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| total, n=122, n=126, n=128 | cognitive toxicity, n=126, n=129, n=128 | somatomotor toxicity, n=122, n=126, n=129 | |
| Duloxetine | -8.92 | -6.23 | -2.58 |
| Gabapentin + Duloxetine | -7.29 | -5.29 | -1.91 |
| Pregabalin | -6.27 | -5.12 | -1.36 |
14-item subject-rated scale assessing medication related changes in sexual activity + functioning. Structured interview/questionnaire. It measures five dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; and orgasm. The total score is obtained across all 5 dimensions, ranging from 14 to 70. Subscale score ranges: desire/frequency=2-10; desire/interest=3-15; pleasure=1-5; arousal=3-15; orgasm=3-15. Higher scores = better sexual functioning. Least-squares means: adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| male, total; n=62, n=67, n=66 | female, total; n=39; n=42, n=43 | male, pleasure; n=64, n=67, n=69 | female, pleasure; n=40, n=42, n=43 | male, desire/frequency; n=65, n=67, n=69 | female, desire/frequency; n=42, n=42, n=43 | male, desire/interest; n=65, n=67, n=70 | female, desire/interest; n=42, n=42, n=45 | male, arousal; n=65, n=67, n=70 | female, arousal; n=40, n=42, n=45 | male, orgasm; n=64, n=67, n=69 | female, orgasm; n=40, n=42, n=43 | |
| Duloxetine | 0.48 | 1.12 | -0.06 | 0.47 | 0.06 | 0.26 | -0.19 | 0.34 | 0.52 | 0.07 | 0.18 | -0.05 |
| Gabapentin + Duloxetine | 1.29 | -0.61 | 0.13 | -0.09 | 0.16 | 0.30 | 0.05 | 0.01 | 0.52 | -0.30 | 0.17 | -0.85 |
| Pregabalin | -0.53 | -0.01 | 0.08 | 0.15 | -0.02 | 0.21 | -0.27 | -0.17 | 0.17 | -0.11 | -0.39 | 0.31 |
The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total scores range from 0 to 30, higher values indicate greater disruption in the patient's life. Item 1 assesses the effect of the patient's symptoms on their work/school schedule, Item 2 on their social life/leisure activities, and Item 3 on their family life/home responsibilities. Subscales scores range: 0-10, higher values indicate greater disruption in the patient's life. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Total | Item 1 | Item 2 | Item 3 | |
| Duloxetine | -3.47 | -1.21 | -1.12 | -1.17 |
| Gabapentin + Duloxetine | -4.54 | -1.95 | -1.53 | -1.54 |
| Pregabalin | -4.96 | -1.96 | -1.64 | -1.70 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | micromole/liter (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 8.07 | -0.28 |
| Gabapentin + Duloxetine | 8.23 | -0.42 |
| Pregabalin | 8.43 | -0.51 |
"Treatment-emergent high body weight: weight at last visit >=107% of baseline weight.~Treatment-emergent low body weight: weight at last visit <=93% of baseline weight." (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| high | low | |
| Duloxetine | 1 | 10 |
| Gabapentin + Duloxetine | 3 | 8 |
| Pregabalin | 6 | 2 |
"Elevated systolic blood pressure: >=130 millimeter mercury (mm Hg) + an increase of >=10 mm Hg if baseline <130 mm Hg.~Elevated diastolic blood pressure: >=85 mm Hg + an increase of >=10 mm Hg if baseline <85 mm Hg." (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| diastolic, n=94, n=98, n=100 | systolic, n=42, n=39, n=56 | |
| Duloxetine | 12 | 15 |
| Gabapentin + Duloxetine | 13 | 16 |
| Pregabalin | 11 | 20 |
Treatment-emergent: within range at baseline, out of range after baseline. Ranges in Units/Liter (U/L). Aspartate Aminotransferase (AST): female (f): >34, male (m): >36. Alanine Aminotransferase (ALT): f:<69 years (yr) >34, ≥69yr >32; m: <69yr >43, ≥69yr >35. Total Bilirubin (TBili): >21. Gamma Glutamyl Transferase (GGT): f: <59yr >49, ≥59yr >50; m: <59yr >61, ≥59yr >50. Fasting Plasma Glucose (FPG): <59yr >6.4, ≥59yr >6.7. Hemoglobin A1C (HbA1C) >6%. Alkaline Phosphatase (AlkPhos): f: 18-50yr >106, 50-70yr >123, 70-80yr >164, ≥80yr >221; m: 18-50yr >129, 50-70yr >131, 70-80yr >156, ≥80yr >187 (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| AST, n=113, n=116, n=109 | ALT, n=111, n=104, n=110 | TBili, n=119, n=121, n=116 | GGT, n=102, n=105, n=96 | FPG, n=33, n=30, n=36 | HbA1C, n=17, n=18, n=29 | AlkPhos, n=112, n=114, n=113 | |
| Duloxetine | 6 | 6 | 0 | 6 | 11 | 2 | 3 |
| Gabapentin + Duloxetine | 4 | 10 | 0 | 6 | 18 | 10 | 4 |
| Pregabalin | 4 | 3 | 2 | 2 | 7 | 6 | 4 |
Contribution to reduction in pain directly by treatment and indirectly by treatment through the reduction of depressive symptoms using path analysis. The direct treatment effect estimates the mean drug difference in pain reduction directly through treatment; the indirect treatment effect estimates the contribution that treatment plays to the mean drug difference in pain reduction indirectly through the reduction in mood symptoms; the total effect estimates the drug difference in reducing pain in sum through the specified path of direct and indirect treatment effects. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | coefficient (Number) | ||
|---|---|---|---|
| Direct Treatment Effect | Indirect Treatment Effect | Total Treatment Effect | |
| Ordinary Coefficient | -0.449 | 0.014 | -0.435 |
(NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nausea | Peripheral Oedema | Insomnia | Somnolence | Anxiety | Dizziness | Dysuria | Headache | Hyperhidrosis | Sedation | Allergic Oedema | Anorgasmia | Increased Blood Creatine | Increased Blood Glucose | Bruxism | Cerebrovascular Accident | Chest Discomfort | Depression | Dermatitis | Diarrhoea | Dry mouth | Enterovirus Infection | Fatigue | Generalized Oedema | Facial Hypoaesthesia | Lacunar Infarction | Loss of Consciousness | Lymphoma | Mental Impairment | Muscular Weakness | Myoclonus | Pollakiuria | Pulomnary Embolism | Rash | Sleep Disorder | Urticaria | Vomiting | |
| Duloxetine | 4 | 0 | 4 | 2 | 1 | 0 | 2 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Gabapentin + Duloxetine | 4 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Pregabalin | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Ordinal scale: 0=no pain, 10=worst possible pain. Data=weekly mean of scores of average pain severity over last 24 hours (h). Scores: daily assessments recorded by patients in diaries. Only patients adhering to key protocol criteria included: baseline Weekly Mean 24h Average Pain Score ≥4; 80-120% compliant with study Drug, each visit; baseline Michigan Neuropathy Screening Instrument Physical Assessment Total Score ≥3; gabapentin taper ≤14 days, no HbA1c ≥12% post randomization; no contraindicated medications used. Least-squares means=adjustment due to baseline severity + investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 6.02 | -2.58 |
| Gabapentin + Duloxetine | 5.74 | -2.40 |
| Pregabalin | 5.74 | -2.12 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. De novo: use of gabapentin for <56 contiguous days prior to randomization. Prior use: use of gabapentin for >=56 contiguous days prior to randomization. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| de novo, baseline | de novo, week 1 | de novo, week 2 | de novo, week 3 | de novo, week 4 | de novo, week 5 | de novo, week 6 | de novo, week 7 | de novo, week 8 | de novo, week 9 | de novo, week 10 | de novo, week 11 | de novo, week 12 | prior use, baseline | prior use, week 1 | prior use, week 2 | prior use, week 3 | prior use, week 4 | prior use, week 5 | prior use, week 6 | prior use, week 7 | prior use, week 8 | prior use, week 9 | prior use, week 10 | prior use, week 11 | prior use, week 12 | |
| Duloxetine | 5.39 | -0.71 | -1.22 | -1.83 | -2.35 | -2.65 | -2.64 | -2.73 | -2.78 | -2.89 | -2.86 | -2.98 | -3.08 | 5.99 | -0.48 | -0.99 | -1.32 | -1.61 | -1.95 | -2.03 | -2.14 | -2.16 | -2.38 | -2.45 | -2.46 | -2.46 |
| Gabapentin + Duloxetine | 5.49 | -0.38 | -1.10 | -1.62 | -1.67 | -1.81 | -1.88 | -2.07 | -2.06 | -2.10 | -1.92 | -2.09 | -2.10 | 5.92 | -0.65 | -1.28 | -1.68 | -1.75 | -1.96 | -1.98 | -2.17 | -2.31 | -2.37 | -2.44 | -2.41 | -2.53 |
| Pregabalin | 5.24 | -0.22 | -0.39 | -0.71 | -0.84 | -0.95 | -1.09 | -1.08 | -1.26 | -1.21 | -1.42 | -1.48 | -1.62 | 5.91 | -0.30 | -0.70 | -1.18 | -1.64 | -1.72 | -1.92 | -1.93 | -1.89 | -2.04 | -2.14 | -2.27 | -2.39 |
24 reviews available for gabapentin and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain.
Topics: Amines; Analgesics; Animals; Anticonvulsants; Calcium Channels; Carboxylic Acids; Cyclohexanecarboxy | 2007 |
Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.
Topics: Analgesics; Antibodies, Monoclonal; Gabapentin; Gangliosides; Humans; Morphine; Neoplasm Metastasis; | 2021 |
Notalgia paresthetica treated with low dose of gabapentin: Case report and literature review.
Topics: Gabapentin; Humans; Peripheral Nervous System Diseases; Pruritus; Skin Diseases | 2020 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics.
Topics: Amines; Analgesics, Opioid; Animals; Antidepressive Agents; Antineoplastic Agents; Cisplatin; Cycloh | 2016 |
Itch Management: Systemic Agents.
Topics: Amines; Analgesics; Analgesics, Opioid; Anion Exchange Resins; Antidepressive Agents; Aprepitant; Ch | 2016 |
Neurologic Itch Management.
Topics: Acupuncture Therapy; Amines; Anesthetics, Local; Anticonvulsants; Antipruritics; Botulinum Toxins, T | 2016 |
Pregabalin in the treatment of chronic pain: an overview.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic | 2009 |
[Pain relief by gabapentin via supraspinal mechanisms in neuropathic conditions].
Topics: Amines; Analgesics; Animals; Brain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid | 2009 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
Gabapentin for the treatment of cancer-related pain syndromes.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2010 |
[Burning sensation in oral cavity--burning mouth syndrome in everyday medical practice].
Topics: Acetamides; Amines; Anti-Anxiety Agents; Antidepressive Agents; Antioxidants; Burning Mouth Syndrome | 2012 |
Mode of action of gabapentin in chronic neuropathic pain syndromes. A short review about its cellular mechanisms in nociceptive neurotransmission.
Topics: Acetates; Amines; Animals; Biogenic Monoamines; Calcium Channels; Chronic Disease; Cyclohexanecarbox | 2002 |
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anticonvu | 2003 |
Gabapentin in the treatment of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2004 |
'Protective premedication': an option with gabapentin and related drugs? A review of gabapentin and pregabalin in in the treatment of post-operative pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Human | 2004 |
[Evidence-based pharmacotherapy of neuropathic pain syndromes].
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Antioxidants; Cyclohexanec | 2004 |
Combination pharmacotherapy for neuropathic pain: current evidence and future directions.
Topics: Amines; Analgesics; Animals; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Synergism; | 2005 |
The mechanism of action of gabapentin in neuropathic pain.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Binding Sites; Calcium Channels; Cyclohexanecarboxylic Ac | 2006 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Antiepileptic drugs in the treatment of neuropathic pain.
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Fructose; Gabapentin; gamma-Ami | 2007 |
Treatment of painful neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gaba | 2007 |
Managing neuropathic pain.
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Calcium Channel Blockers; Combined Modality Therapy; Cy | 2007 |
Gabapentin use in neuropathic pain syndromes.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2000 |
21 trials available for gabapentin and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Randomized double-blind, placebo-controlled study of oral gabapentin for prevention of neuropathy in patients receiving paclitaxel.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Gabapent | 2023 |
Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Female; Gabapentin; Humans; Male; | 2018 |
Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Double-Blind Method; Female; Gabapentin; | 2019 |
Is gabapentin effective in dry eye disease and neuropathic ocular pain?
Topics: Adult; Analgesics; Dry Eye Syndromes; Eye Pain; Female; Gabapentin; Humans; Male; Middle Aged; Pain; | 2021 |
Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients.
Topics: Adult; Aged; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Female; Follow-Up | 2013 |
Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combi | 2014 |
Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.
Topics: Acute Pain; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2016 |
Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies.
Topics: Adolescent; Adult; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Diphenhydram | 2009 |
Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; | 2009 |
Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; | 2010 |
Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial.
Topics: Amines; Anti-Anxiety Agents; Calcium Channel Blockers; Cross-Over Studies; Cyclohexanecarboxylic Aci | 2013 |
Clinical efficacy of gabapentin for paroxysmal symptoms in multiple sclerosis.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 2004 |
A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2004 |
Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study.
Topics: Aged; Amines; Analgesics; Analysis of Variance; Cyclohexanecarboxylic Acids; Dose-Response Relations | 2005 |
Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions.
Topics: Adult; Age Distribution; Aged; Amines; Analgesics; Cohort Studies; Cross-Sectional Studies; Cyclohex | 2007 |
Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain.
Topics: Adult; Aged; Amines; Analgesics; Anxiety; Cyclohexanecarboxylic Acids; Depression; Disability Evalua | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antineoplastic Agents; Cross-Over Studies; Cyclo | 2007 |
Gabapentin adjunctive therapy in neuropathic pain states.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Facial Pain; Female; Gabapen | 1996 |
The effect of gabapentin on neuropathic pain.
Topics: Acetates; Adolescent; Adult; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Gabapentin; gam | 1997 |
Gabapentin for treatment of pain and tremor: a large case series.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Arachnoiditis; Cerebellar Neoplasms; Cyc | 1998 |
Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Central Nervous System Diseases; Cyclohexanecarboxyli | 1998 |
71 other studies available for gabapentin and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; gamma-Aminobutyric Acid; Hyperalgesia; | 2007 |
Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective
Topics: Administration, Oral; Analgesics; Animals; Cell Line; Drug Tolerance; Fluoroquinolones; Humans; In V | 2010 |
Persistent sensory changes and sex differences in transgenic mice conditionally expressing HIV-1 Tat regulatory protein.
Topics: Animals; Cryopyrin-Associated Periodic Syndromes; Doxycycline; Female; Gabapentin; Gene Products, ta | 2022 |
Gabapentin treatment in notalgia paresthetica: a preliminary report.
Topics: Adult; Back; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gabapentin; Hum | 2020 |
Association of out-of-pocket costs on adherence to common neurologic medications.
Topics: Adult; Aged; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Excitatory Amino Acid Antago | 2020 |
Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices.
Topics: Adult; Amitriptyline; Antineoplastic Agents; Calcium; Cross-Sectional Studies; Duloxetine Hydrochlor | 2021 |
Efficiencies of Low-Level Laser Therapy (LLLT) and Gabapentin in the Management of Peripheral Neuropathy: Diabetic Neuropathy.
Topics: Amines; Animals; Combined Modality Therapy; Creatinine; Cyclohexanecarboxylic Acids; Cytokines; Diab | 2018 |
Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy.
Topics: Adult; Amines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclohexanecarboxylic Ac | 2018 |
[On the Differential Diagnosis of Intractable Psychogenic Chronic Cough: Neuropathic Larynx Irritable - Gabapentin's Antitussive Action].
Topics: Aged; Amines; Avitaminosis; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Depressive Disorder | 2015 |
Therapeutic Implications of Peripheral Nerve Hyperexcitability in Muscle Cramping: A Retrospective Review.
Topics: Amines; Analgesics, Non-Narcotic; Antibodies; Carbamazepine; Cyclohexanecarboxylic Acids; Electric S | 2016 |
Multilevel symmetric neuropathic pruritus (MSNP) presenting as recalcitrant "generalized" pruritus.
Topics: Age Distribution; Aged; Amines; Chronic Disease; Cohort Studies; Cyclohexanecarboxylic Acids; Diseas | 2016 |
Multiplicative interactions to enhance gabapentin to treat neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Donepezil; Dose-Response Relationship, Dru | 2008 |
Neuropathic pain in children after exposure to mercury.
Topics: Amines; Analgesics, Non-Narcotic; Burning Mouth Syndrome; Child; Cyclohexanecarboxylic Acids; Gabape | 2008 |
A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling.
Topics: Adult; Aged; Algorithms; Amines; Area Under Curve; Bayes Theorem; Biological Availability; Cyclohexa | 2009 |
Peripheral neuropathy in an adolescent treated with linezolid.
Topics: Acetamides; Amines; Analgesics; Anti-Bacterial Agents; Child; Cyclohexanecarboxylic Acids; Female; G | 2009 |
Topical analgesic combinations for bortezomib neuropathy.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Amines; Analgesics; Boronic Acids; Bortezomib; C | 2009 |
Alopecia associated with gabapentin in the treatment of neuropathic pain.
Topics: Alopecia; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A | 2009 |
Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit.
Topics: Administration, Oral; Amines; Analgesics, Non-Narcotic; Animals; Antineoplastic Agents; Antineoplast | 2009 |
A mouse model of sural nerve injury-induced neuropathy: gabapentin inhibits pain-related behaviors and the hyperactivity of wide-dynamic range neurons in the dorsal horn.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Behavior, Animal; Cold Temperature; Cyclohexanecarboxylic | 2009 |
Blood serum profiling of the rat spinal nerve ligation model using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry.
Topics: Amines; Analgesics; Animals; Biomarkers; Chromatography, High Pressure Liquid; Cyclohexanecarboxylic | 2009 |
[Obturator nerve lesion after a vaginal delivery without instrumentation under epidural analgesia].
Topics: Adult; Amines; Analgesia, Epidural; Analgesia, Obstetrical; Analgesics; Cyclohexanecarboxylic Acids; | 2009 |
How does gabapentin relieve neuropathic pain?
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pain; | 2009 |
Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy.
Topics: Aged; Amines; Analgesics; Cohort Studies; Cyclohexanecarboxylic Acids; Data Interpretation, Statisti | 2010 |
Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
Topics: Amines; Analgesics, Opioid; Animals; Carrageenan; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ex | 2010 |
New uses for older drugs: the tales of aspirin, thalidomide, and gabapentin.
Topics: Amines; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Aspirin; Cyclohexanecarboxylic Aci | 2010 |
Non-length-dependent small fibre neuropathy. Confocal microscopy study of the corneal innervation.
Topics: Adult; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Second-Generation; Antidepressive A | 2010 |
A tropomyosine receptor kinase inhibitor blocks spinal neuroplasticity essential for the anti-hypersensitivity effects of gabapentin and clonidine in rats with peripheral nerve injury.
Topics: Acetylcholine; Amines; Analgesics; Animals; Carbazoles; Choline O-Acetyltransferase; Clonidine; Cycl | 2011 |
Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
Topics: Aged; Amines; Analgesics; Case-Control Studies; Clinical Trials as Topic; Cyclohexanecarboxylic Acid | 2010 |
Gabapentin withdrawal syndrome in a post-liver transplant patient.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2010 |
Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies.
Topics: Amines; Analgesics; Animals; Cholinesterase Inhibitors; Cyclohexanecarboxylic Acids; Disease Models, | 2010 |
Neuritis ossificans of the tibial, common peroneal and lateral sural cutaneous nerves.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans | 2011 |
Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.
Topics: Aged; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; | 2012 |
Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure.
Topics: Aged; Aged, 80 and over; Amines; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Ne | 2012 |
Peripheral nerve toxic effects of nitrofurantoin.
Topics: Amines; Analgesics; Anti-Infective Agents, Urinary; Biopsy; Cyclohexanecarboxylic Acids; Cystitis, I | 2012 |
Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment.
Topics: Adrenal Cortex Hormones; Aged; Amines; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Ca | 2013 |
Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model.
Topics: Amines; Animals; Antioxidants; Calcium Channels; Catalase; Cyclohexanecarboxylic Acids; Drug Combina | 2013 |
Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain.
Topics: Acetates; Amines; Animals; Benzofurans; Carbamates; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2002 |
Anti-allodynic action of the tormentic acid, a triterpene isolated from plant, against neuropathic and inflammatory persistent pain in mice.
Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Freund' | 2002 |
ATP-sensitive potassium channels in rat primary afferent neurons: the effect of neuropathic injury and gabapentin.
Topics: Acetates; Amines; Animals; ATP-Binding Cassette Transporters; Basal Ganglia; Cyclohexanecarboxylic A | 2003 |
Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats.
Topics: Acetates; Amines; Analgesics; Animals; Anticonvulsants; Calcium Channel Blockers; Carbamazepine; Cyc | 2003 |
Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain.
Topics: Acetates; Amines; Analgesics; Animals; Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Edema; | 2003 |
Synergistic interaction between spinal gabapentin and oral B vitamins in a neuropathic pain model.
Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug | 2003 |
The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
Topics: Acute Disease; Amines; Analgesics, Opioid; Animals; Carbamates; Cyclohexanecarboxylic Acids; Disease | 2004 |
Future Pain Drugs - Europe 2003. 15-16 September 2003, London, UK.
Topics: Acetaminophen; Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, A | 2003 |
Differential analgesic sensitivity of two distinct neuropathic pain models.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Animals; Cold Temperature; Cyclohexanecarboxylic A | 2004 |
Gabapentin relieves mechanical, warm and cold allodynia in a rat model of peripheral neuropathy.
Topics: Amines; Animals; Cold Temperature; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Respons | 2004 |
Neutropenia occurring after starting gabapentin for neuropathic pain.
Topics: Adenocarcinoma; Amines; Analgesics; Carcinoma, Non-Small-Cell Lung; Cyclohexanecarboxylic Acids; Gab | 2004 |
Oral administration of B vitamins increases the antiallodynic effect of gabapentin in the rat.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Syn | 2004 |
Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and review.
Topics: Adolescent; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cerebral Palsy; Chi | 2005 |
Effects of gabapentin on spontaneous discharges and subthreshold membrane potential oscillation of type A neurons in injured DRG.
Topics: Amines; Analgesics; Animals; Animals, Newborn; Cyclohexanecarboxylic Acids; Differential Threshold; | 2005 |
The effect of antinociceptive drugs tested at different times after nerve injury in rats.
Topics: Amines; Analgesics; Animals; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Dose-Res | 2005 |
Characterization of pain and pharmacologic responses in an animal model of lumbar adhesive arachnoiditis.
Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Arachnoiditis; Behavior, Animal; Cauda Equina; Cycl | 2005 |
Neuropathies in the rheumatoid patient: a case of the heavy hand.
Topics: Amines; Arthritis, Rheumatoid; Cyclohexanecarboxylic Acids; Electromyography; Female; Follow-Up Stud | 2005 |
Development and expression of neuropathic pain in CB1 knockout mice.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2006 |
Differential pharmacological modulation of the spontaneous stimulus-independent activity in the rat spinal cord following peripheral nerve injury.
Topics: Action Potentials; Amines; Analgesics; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarbox | 2006 |
Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin.
Topics: Amines; Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Blotting, Western; Calcium Cha | 2006 |
A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain.
Topics: Amines; Analgesics; Animals; Anticonvulsants; Cold Temperature; Cyclohexanecarboxylic Acids; Disease | 2007 |
Laryngeal neuropathy as a cause of chronic intractable cough.
Topics: Amines; Cough; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Ami | 2007 |
Nociception: Taking the Pain out of Drug Discovery. 28 November 2006, London, UK.
Topics: Amidohydrolases; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2007 |
Gabapentin treatment for notalgia paresthetica, a common isolated peripheral sensory neuropathy.
Topics: Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric A | 2007 |
Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice.
Topics: Amines; Animals; Cyclic AMP-Dependent Protein Kinases; Cyclohexanecarboxylic Acids; Efferent Pathway | 2008 |
Gabapentin and sexual dysfunction: report of two cases.
Topics: Adolescent; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2008 |
Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice.
Topics: Amines; Amitriptyline; Animals; Anticonvulsants; Antidepressive Agents, Tricyclic; Brain; Chronic Di | 2008 |
Pharmacological treatment of neuropathic pain in older persons.
Topics: Aged; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Chronic Disease | 2008 |
HIV neuropathy treated with gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 1998 |
Gabapentin for lancinating neuropathic pain.
Topics: Acetates; Acquired Immunodeficiency Syndrome; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabap | 1998 |
Comments on Gould, PAIN, 74 (1998) 341-343.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamm | 1998 |
Neuropathic pain after anti-HIV gene therapy successfully treated with gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 1999 |
Morphine and gabapentin decrease mechanical hyperalgesia and escape/avoidance behavior in a rat model of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Animals; Avoidance Learning; Cyclohexanecarboxylic Acids; Disease Mode | 2000 |
Recurrent hypoventilation and respiratory failure during gabapentin therapy.
Topics: Acetates; Aged; Amines; Analgesics; Anti-Anxiety Agents; Anticonvulsants; Cyclohexanecarboxylic Acid | 2001 |
The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats.
Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Res | 2001 |